Possibly - at least they are putting their targeted drug development program back where it needs it be .....aimed directly at therapeutic medical benefit - Mark Levin is no mug and would not jeopardise reputational standing on fluff imo this is potentially an investigational study of ZTL-106s' ability to establish itself as a treatment - validated, efficacious treatment with demonstrated safety profile and demonstrated therapeutic benefit for athletes suffering chronic pain. The importance of this trial at this time is immense imo - Levin likes what it sees and understands the relevance and product differentiation ($$$$$_ ) linked with quality clinical trial data. they are putting their money where their mouth is by funding the trial so Zelira have it on a plate imo - can they execute is the question - as always it remains to be seen - hope so finally Everything else in the sector that does not pursue this route ( clinically validated trial outcomes) is thumb twiddling in the blackmores category......fluff and fairy dust imo
all the best to them in this trial and the desired outcomes
